Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06902623 · ClinicalTrials.gov registry record · NA
Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
A NA study of Hpv and Tonsil Cancer, sponsored by Georgetown University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06902623 is a NA study of Hpv and Tonsil Cancer that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 30 participants, below the 2,240-participant average among 24 other Hpv trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06902623, a NA study of Hpv and Tonsil Cancer, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into question whether therapy can be decreased in intensity since both chemotherapy and radiation have long-term side effects. One approach to decrease intensity of treatment is to give radiation alone (excluding chemotherapy) and to decrease radiation therapy dose. The investigator believes that omitting chemotherapy and decreasing radiation dose both to tumor and the regions of the head and neck at highest risk of potential spread, may have no significant impact on the cancer recurring while potentially leading to fewer long-term side effects.
Conditions Studied
Interventions
- RADIATION Radiation
Study Locations (2)
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Maryland
- Medstar Southern Maryland Hospital Center - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2030-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06902623
The ClinicalTrials.gov registry entry for NCT06902623 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,240-participant average among 24 other Hpv trials with a reported enrollment target (99% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hpv appearing as the primary indexed condition, and to 1 intervention - of which Radiation is the first listed.
NCT06902623 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT06902623 about?
NCT06902623 is a clinical study titled "Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy". The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into question whether therapy ...
What is the current status of trial NCT06902623?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-08-01. Estimated completion is 2030-12-31.
What conditions does trial NCT06902623 study?
This clinical trial studies the following conditions: Hpv, Tonsil Cancer, Oropharyngeal Cancers, Base of Tongue Cancer.
What interventions are being tested in trial NCT06902623?
The interventions under investigation include: Radiation (RADIATION).
Who is sponsoring clinical trial NCT06902623?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06902623 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hpv
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
RECRUITING · NA
-
HPV Self-Collection Program
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
-
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
RECRUITING · NA
-
Playing Game to Learn About Children's Vaccine Project
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.